...biosimilar, on Monday revealed it will sell its biosimilar business to partner Biocon Biologics in a $3.3 billion deal. This includes Semglee, the insulin interchangeable with Sanofi’s Lantus. The drug launched in November 2021. For the treatment of type 2 diabetes, Semglee currently holds covered or better status for 59% of all insured lives, to Lantus’ 70%.
SOURCE: MMIT Analytics, as of 3/1/22
No comments:
Post a Comment